Published in J Virol on March 01, 2006
Prevalence of occult hepatitis B amongst Indian human immunodeficiency virus type 1 infected individuals-a pilot study. Med J Armed Forces India (2012) 1.44
Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China. J Virol (2013) 1.31
Hepatitis B virus S gene escape mutants. Asian J Transfus Sci (2007) 1.14
Naturally occurring mutations in large surface genes related to occult infection of hepatitis B virus genotype C. PLoS One (2013) 1.11
Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome. PLoS One (2012) 1.06
Hepatitis B virus infection is associated with gastric cancer in China: an endemic area of both diseases. Br J Cancer (2015) 0.95
Atypical serological profiles in hepatitis B virus infection. Eur J Clin Microbiol Infect Dis (2012) 0.88
Analysis of complete nucleotide sequences of Angolan hepatitis B virus isolates reveals the existence of a separate lineage within genotype E. PLoS One (2014) 0.87
Occult infection related hepatitis B surface antigen variants showing lowered secretion capacity. World J Gastroenterol (2015) 0.87
Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother (2009) 0.86
Quasispecies structure, cornerstone of hepatitis B virus infection: mass sequencing approach. World J Gastroenterol (2013) 0.84
The underlying mechanisms for the "simultaneous HBsAg and anti-HBs serological profile". Eur J Clin Microbiol Infect Dis (2011) 0.84
Occult hepatitis B in blood donors: a description of two cases. Blood Transfus (2010) 0.83
Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection. Mol Biol Rep (2013) 0.82
Genetic variation of hepatitis B virus and its significance for pathogenesis. World J Gastroenterol (2016) 0.82
Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy. Chin Med J (Engl) (2016) 0.79
Association of preS/S Mutations with Occult Hepatitis B Virus (HBV) Infection in South Korea: Transmission Potential of Distinct Occult HBV Variants. Int J Mol Sci (2015) 0.79
Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination. BMC Gastroenterol (2014) 0.77
Infection with hepatitis B virus carrying novel pre-S/S gene mutations in female siblings vaccinated at birth: two case reports. J Med Case Rep (2010) 0.76
Should hepatitis B serosurveys methodology be reconsidered? Am J Trop Med Hyg (2010) 0.75
Clinical features and viral quasispecies characteristics associated with infection by the hepatitis B virus G145R immune escape mutant. Emerg Microbes Infect (2017) 0.75
Evaluation of the G145R Mutant of the Hepatitis B Virus as a Minor Strain in Mother-to-Child Transmission. PLoS One (2016) 0.75
Detection of hepatitis B virus isolates with mutations associated with immune escape mutants among pregnant women in Ibadan, southwestern Nigeria. Springerplus (2015) 0.75
Hepatitis B surface antigen escape mutations: Indications for initiation of antiviral therapy revisited. World J Clin Cases (2016) 0.75
Clinical and Virological Characteristics of Chronic Hepatitis B Patients with Coexistence of HBsAg and Anti-HBs. PLoS One (2016) 0.75
Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B. PLoS One (2014) 0.75
Genetic variation of occult hepatitis B virus infection. World J Gastroenterol (2016) 0.75
Molecular epidemiology and clinical characteristics of hepatitis B identified through the French mandatory notification system. PLoS One (2013) 0.75
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res (1997) 175.36
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat (2004) 13.18
Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol (2005) 9.00
The hepatitis B virus. Nature (1985) 8.71
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
Viral hepatitis B. Lancet (2003) 4.86
A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol (1995) 3.35
Fulminant reactivation of hepatitis B due to envelope protein mutant that escaped detection by monoclonal HBsAg ELISA. Lancet (1995) 2.82
A web-based genotyping resource for viral sequences. Nucleic Acids Res (2004) 2.68
Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology (1998) 2.19
Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol (1994) 2.05
Hepatitis B virus: significance of genotypes. J Viral Hepat (2005) 1.87
The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol (2002) 1.71
Vaccine- and hepatitis B immune globulin-induced escape mutations of hepatitis B virus surface antigen. J Biomed Sci (2001) 1.61
Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology (2001) 1.61
A topological model for hepatitis B surface antigen. Intervirology (1992) 1.59
The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat (1997) 1.58
Wild-type and 'a' epitope variants in chronic hepatitis B virus carriers positive for hepatitis B surface antigen and antibody. J Gastroenterol Hepatol (2002) 1.50
Survey of hepatitis B surface variant infection in children 15 years after a nationwide vaccination programme in Taiwan. Gut (2004) 1.42
Hepatitis B infection: pathogenesis and management. J Hepatol (2000) 1.42
Immunoassay detection of hepatitis B surface antigen mutants. J Med Virol (1999) 1.34
Genetic variability of the S gene of hepatitis B virus: clinical and diagnostic impact. J Clin Virol (2005) 1.28
Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol (2004) 1.24
Hepatitis B virus S gene mutants in a patient with chronic active hepatitis with circulating Anti-HBs antibodies. J Med Virol (2003) 1.06
Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. J Infect Dis (1999) 1.00
Detection of different viral strains of hepatitis B virus in chronically infected children after seroconversion from HBsAg to anti-HBs indicating viral persistence. J Hepatol (1997) 1.00
Presence of hepatitis B surface antigen mutant G145R DNA in the peripheral blood leukocytes of the family members of an asymptomatic carrier and evidence of its horizontal transmission. Virus Res (2002) 1.00
Mutations in the envelope gene of hepatitis B virus variants co-occurring with antibody to surface antigen in sera from patients with chronic hepatitis B. J Gen Virol (1996) 0.92
Characterization of a novel hepatitis B virus mutant: demonstration of mutation-induced hepatitis B virus surface antigen group specific "a" determinant conformation change and its application in diagnostic assays. Transfus Med (2001) 0.91
Sequential changes in full-length genomes of hepatitis B virus accompanying acute exacerbation of chronic hepatitis B. J Hepatol (1996) 0.90
Hepatitis B virus escape mutants: "pushing the envelope" of chronic hepatitis B virus infection. Hepatology (1995) 0.89
A quasi-monoclonal anti-HBs response can lead to immune escape of 'wild-type' hepatitis B virus. J Gen Virol (2005) 0.87
Mutations that change the immunological subtype of hepatitis B virus surface antigen and distinguish between antigenic and immunogenic determination. J Med Virol (1989) 0.87
Naturally occurring hepatitis B surface gene variants in chronic hepatitis B virus infection: correlation with viral serotypes and clinical stages of liver disease. J Med Virol (2002) 0.86
Selection of a secretion-incompetent mutant in the serum of a patient with severe hepatitis B. Gastroenterology (2003) 0.86
Variants of two major T cell epitopes within the hepatitis B surface antigen are not recognized by specific T helper cells of vaccinated individuals. Hepatology (2002) 0.86
Hepatitis B virus (HBV) vaccine-induced escape mutants of HBV S gene among children from Qidong area, China. Virus Res (2004) 0.85
Specificity of antibodies reactive with hepatitis B surface antigen following immunization with synthetic peptides. Vaccine (1993) 0.84
Natural history of hepatitis B surface antigen mutants in children. Lancet (1996) 0.82
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology (2009) 5.87
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol (2013) 5.64
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Viral hepatitis B. Lancet (2003) 4.86
Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol (2009) 4.82
Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med (2011) 4.39
Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem (2004) 3.45
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology (2004) 3.19
Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology (2008) 3.15
Truth survival in clinical research: an evidence-based requiem? Ann Intern Med (2002) 2.87
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology (2009) 2.79
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int (2011) 2.77
Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (2013) 2.62
Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol (2005) 2.62
Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS (2003) 2.58
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol (2009) 2.39
Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology (2003) 2.23
Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol (2003) 2.19
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol (2004) 2.19
Immediate listing for liver transplantation versus standard care for Child-Pugh stage B alcoholic cirrhosis: a randomized trial. Ann Intern Med (2009) 2.16
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology (2010) 2.13
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis (2003) 2.11
IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology (2011) 2.11
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology (2009) 2.10
Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum (2006) 2.09
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 2.08
Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology (2004) 2.08
Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol (2007) 2.08
Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology (2002) 2.06
Anti-tumor necrosis factor-alpha therapy in severe alcoholic hepatitis: are large randomized trials still possible? J Hepatol (2003) 2.04
Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology (2002) 2.02
Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS (2007) 2.00
Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology (2012) 1.95
Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study. Hepatology (2002) 1.94
Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.86
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. Clin Chem (2007) 1.84
Liver damage underlying unexplained transaminase elevation in human immunodeficiency virus-1 mono-infected patients on antiretroviral therapy. Hepatology (2009) 1.84
A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol (2013) 1.84
A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem (2006) 1.78
A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology (2005) 1.76
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS (2005) 1.71
Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology (2011) 1.71
Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology (2008) 1.70
Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. J Cyst Fibros (2013) 1.66
Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol (2005) 1.63
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol (2010) 1.63
Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol (2006) 1.63
Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred. J Hepatol (2010) 1.60
Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol (2004) 1.57
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C. Gut (2010) 1.55
Changing electrolyte and acido-basic profile in HIV-infected patients in the HAART era. Nephron Physiol (2006) 1.51
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer (2007) 1.51
High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. Hepatology (2007) 1.50
Treatment of hepatitis C virus in human immunodeficiency virus infected patients in "real life": modifications in two large surveys between 2004 and 2006. J Hepatol (2007) 1.48
HCV-GenoFibrotest: a combination of viral, liver and genomic (IL28b, ITPA, UGT1A1) biomarkers for predicting treatment response in patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol (2011) 1.47
Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol (2005) 1.45
Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur J Gastroenterol Hepatol (2004) 1.44
Liver biopsy: the best standard...when everything else fails. J Hepatol (2009) 1.43
Antiretroviral drugs and liver injury. AIDS (2008) 1.40
Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS (2008) 1.40
Lamivudine and HBV-associated nephropathy. Nephrol Dial Transplant (2005) 1.40
Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology (2002) 1.40
Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med (2004) 1.39
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology (2010) 1.38
Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. Hepatology (2005) 1.38
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol (2005) 1.33
Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology (2007) 1.33
Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol (2007) 1.31
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS (2002) 1.30
Potential exposure to hepatitis C virus through accidental blood contact in interventional radiology. J Vasc Interv Radiol (2003) 1.29
Chronic hepatitis B: preventing, detecting, and managing viral resistance. Clin Gastroenterol Hepatol (2008) 1.29
Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg (2010) 1.28
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol (2005) 1.27
The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. Hepatology (2004) 1.26
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer (2008) 1.25